Exin Therapeutics vs Isomorphic Labs
Side-by-side comparison of features, pricing, and ratings
At a glance
| Dimension | Exin Therapeutics | Isomorphic Labs |
|---|---|---|
| Approach | AI target discovery for neurotherapeutics using multimodal data and neural circuit modeling | AI-first drug discovery built on AlphaFold, focusing on protein-ligand interactions and generative molecule design |
| Key Innovation | Multimodal AI predicting drug effects across neural disorders, bridging animal-to-human translation via neural manifolds | Nobel Prize-winning AlphaFold system integrated into a Drug Design Engine for predictive and generative modeling |
| Target Users | Neuroscience drug discovery researchers, CNS biotech/pharma R&D, academic groups | Large pharma companies seeking deep collaborations for large-scale drug development |
| Partnership Model | Not specified; platform still in development | Deep collaborations with Novartis and Johnson & Johnson; operates solely through pharma partnerships |
| Pricing | Contact for pricing | Contact for pricing |
For neuroscience-focused teams needing AI-driven target discovery with multimodal data and circuit-level insights, Exin Therapeutics is the specialized choice. Isomorphic Labs, with its AlphaFold-based platform and partnerships with Novartis/J&J, is better suited for large pharma collaborations on broad drug development programs. Choose Exin for neuro-specific early discovery; choose Isomorphic for large-scale, protein-centric drug design.
A research-stage AI platform for discovering neurotherapeutics that act on neural circuits across multiple disorders.
Visit Website
Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.
Visit WebsiteWho should pick which
- Neuroscience startup founderPick: Exin Therapeutics
Exin targets early-stage CNS drug discovery with multimodal AI and circuit-level focus, ideal for startups lacking massive datasets but needing novel target identification.
- Big pharma R&D executivePick: Isomorphic Labs
Isomorphic Labs partners with pharma giants like Novartis and J&J for large-scale programs, offering AlphaFold-based protein design and predictive modeling at scale.
- Academic neuroscience researcherPick: Exin Therapeutics
Exin's platform bridges animal-to-human data gaps and provides circuit-level insights, valuable for translational research despite being in development.
- Drug discovery tool investorPick: Isomorphic Labs
Isomorphic Labs has strong financial backing ($600M investment, Series B) and proven partnerships, indicating higher commercialization readiness and market traction.
Frequently Asked Questions
Exin Therapeutics vs Isomorphic Labs: which should you choose?
For neuroscience-focused teams needing AI-driven target discovery with multimodal data and circuit-level insights, Exin Therapeutics is the specialized choice. Isomorphic Labs, with its AlphaFold-based platform and partnerships with Novartis/J&J, is better suited for large pharma collaborations on broad drug development programs. Choose Exin for neuro-specific early discovery; choose Isomorphic for large-scale, protein-centric drug design.
Are these platforms ready to use off-the-shelf?
No. Exin is still in development and not a commercial platform. Isomorphic Labs operates solely through partnerships, not as a standalone product.
Which tool is better for small molecule drug discovery?
Isomorphic Labs, with AlphaFold for protein-ligand interactions and generative molecule design, is more suited for small molecule programs. Exin is modality-agnostic but focuses on target identification.
Can I use these for psychiatric disorders?
Exin specifically targets neuroscience and neural disorders, including psychiatric conditions, using multimodal data. Isomorphic does not specialize in CNS.
Do they offer API access?
Neither platform offers public API access. Exin is in development; Isomorphic's models are used internally in collaborations.
What is the latest funding news for Isomorphic Labs?
Isomorphic closed a Series B round in February 2026 (undisclosed amount) and raised $600M in external investment in March 2025.
Does Exin have any partnerships or published results?
No partnerships or peer-reviewed publications are mentioned in the provided data. The platform is still in development.
Which tool is more cost-effective for a small biotech?
Exin likely offers more flexible pricing for smaller entities, while Isomorphic requires large-scale partnership commitments. Neither has public pricing.
How does Exin's neural circuit approach work?
Exin integrates neural, behavioral, molecular, and clinical data to learn conserved neural manifolds, enabling predictions that generalize from animal to human outcomes.
More Exin Therapeutics or Isomorphic Labs comparisons
These tools are polar opposites in audience and purpose. Ironclaw AI Vision is a free, offline-first PWA for individual fitness tracking with AI coaching and meal planning – ideal for privacy-consciou
Angle and Isomorphic Labs serve completely different domains—Angle is a free, niche pose-measurement tool for fitness professionals, while Isomorphic Labs is an enterprise AI drug discovery platform f
These tools serve completely different markets. CalBye is a consumer nutrition app for individuals wanting effortless calorie tracking via photos, while Isomorphic Labs is an enterprise drug discovery
Choose Ray if you need an adaptive, low-barrier AI personal trainer for flexible, voice-guided workouts — it's ideal for busy individuals wanting consistency without gym intimidation. Choose Isomorphi
MediSphere and Isomorphic Labs serve completely different healthcare verticals. Choose MediSphere if you run a small clinic needing AI-powered administration, no-show prediction, and EHR. Choose Isomo
Isomorphic Labs and Swimio serve completely different worlds: one is a high-stakes pharma AI platform for billion-dollar drug programs, the other a consumer fitness app for swimmers. Choose based on y
Explore each tool further
Browse these categories
One email a week — new tools, honest comparisons, no spam.
Last reviewed: July 3, 2026